Humpath.com - Human pathology

Home > A. Molecular pathology > CDs > CD109

CD109

Monday 14 September 2015

WKP

CD109 is a co-receptor of TGF-β1 and suppresses TGF-β signaling.

CD109 is a GPI-linked cell surface antigen expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial cells, and activated platelets (Lin et al., 2002).

In addition, the platelet-specific Gov antigen system, implicated in refractoriness to platelet transfusion, neonatal alloimmune thrombocytopenia, and posttransfusion purpura, is carried by CD109 (Kelton et al., 1990; Lin et al., 2002).

In this study, CD109 protein expression in three subtypes of gallbladder cancer was examined by immunohistochemistry on human tissue samples and tissue microarrays.

Pathology

- CD109 is specifically expressed in malignant squamous cells in squamous cell carcinomas (86.7%) and adenosquamous carcinomas (91.7%), but not in adenocarcinomas.

- CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder. (26249215)

  • Gallbladder cancer is the most common biliary tract malignancy with the worst overall prognosis.
  • CD109 is specifically expressed in malignant squamous cells in squamous cell carcinomas (86.7%) and adenosquamous carcinomas (91.7%), but not in adenocarcinomas or normal gallbladder tissues.
  • CD109 may be a potential pathology marker for gallbladder squamous cell/adenosquamous carcinomas.

Open references

- CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder. Dong F, Lu C, Chen X, Guo Y, Liu J. Diagn Pathol. 2015 Aug 7;10:137. doi : 10.1186/s13000-015-0375-0 PMID: 26249215 (Free)